Cetuximab in colon cancer

International Journal of Biological Markers

Volumn 22, Issue 1 SUPPL. 4, 2007, Pages

  Giuliani, F ^a   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Monoclonal antibodies

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BENZOYL PEROXIDE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHLORHEXIDINE; CORTICOSTEROID; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MENTHOL; OXALIPLATIN; SALICYLIC ACID; SILVER NITRATE; TETRACYCLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; ECZEMA; GENE EXPRESSION; HUMAN; INHIBITION KINETICS; INOPERABLE CANCER; LIVER METASTASIS; LOADING DRUG DOSE; LOW DRUG DOSE; MALAISE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PARONYCHIA; PATIENT COMPLIANCE; PATIENT SELECTION; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYOGENIC GRANULOMA; SKIN MANIFESTATION; SKIN TOXICITY; SUPERINFECTION; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; XEROSIS;

EID: 34248395013     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.3855     Document Type: Article

References (40)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70.
2. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43.
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (suppl 4): S9-S15.
4. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (suppl 4): S3-S8.
5. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-611.
6. Saltz L, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
7. Lenz H-J, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16S): abstr 3536.
8. Mirtsching B, Cichon J, Beasley S, et al. Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patient and disease variables. J Clin Oncol 2005; 23 (16S): abstr 3671.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
10. Humblet Y, Peeters M, Bleiberg H, et al. An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23 (16S): abstr 3632.
11. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-225 in combination with irinotecan (Cpt-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
12. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (Cpt) is active in Cpt-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: abstr 7.
13. Wilke H, Glynne-Iones R, Thaler J, et al. MABEL - a large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol 2006; 24 (18S): abstr 3557.
14. Sobrero A, Scheitauer W, Maurel J, et al. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomised phase III trial (EPIC). J Clin Oncol 2005; 23 (16S): abstr 3580.
15. Polikoff J, Mitchell PP, Badarinath S, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomised phase III trial. J Clin Oncol 2005; 23 (16S): abstr 3574.
16. Rosemberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (Cpt-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21: abstr 536.
17. Rougier P, Raoul J-L, Van Laethem J-L, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal cancer. J Clin Oncol 2004, 22: abstr 3513.
18. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5 fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment in metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR). Eur J Cancer 2005; 3: abstr 702.
19. Peeters M, Raoul J-L, Van Laethem J-L, et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer 2005, 3: abstr 664.
20. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/ 5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) + cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRQ: CALGB 80203 preliminary results. J Clin Oncol 2006; 24 (18S): abstr 3509.
21. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX-6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
22. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX-4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-75.
23. André T, Tabernero J, van Cutsem E, et al. Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): final results. Proc ASCO GI Cancers Symposium 2007; abstr 344.
24. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J Clin Oncol 2006; 24 (18S): abstr 3559.
25. Dakhil S, Cosgriff T, Headley D, et al. Cetuximab + FOLFOX-6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, 1-03-002). J Clin Oncol 2006; 24 (18S): abstr 3557.
26. Seufferlein T, Dittrich C, Riemann JF, et al. A phase I/II study of cetuximab with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol 2005; 23 (16S): abstr 3644.
27. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-7.
28. Heinemann V, Fischer von Weikersthal L, Moosmann N, et al. Cetuximab + capecitabine + irinotecan (CCD versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): preliminary results of a randomised phase II trial of the AIO CRC Study Group. J Clin Oncol 2006; 24 (18S): abstr 3550.
29. Borner M, Mingrone W, Koeberle D, et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006; 24 (18S): abstr 3551.
30. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine-kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
31. Saltz L, Lenz HJ, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/ bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancers Symposium 2005; abstr 169b.
32. Walon L, Gilbeau C, Lachapell JM, et al. Eruptions acneiformes induìtes par le Cetuximab. Ann Dermatol Venereol 2003; 130: 443-6.
33. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br J Dermatol 2004; 151: 238-41.
34. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76.
35. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefinitib. J Clin Oncol 2005; 23: 165-74.
36. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3: 599-606.
37. Chung KY, Shia J, Kemeny N, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
38. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetics (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24 (18S): abstr 3085.
39. Teipar S, Peeters M, Humblet Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. J Clin Oncol 2006; 24 (18S): abstr 3554.
40. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5.